Vestipitant

Vestipitant
Clinical data
ATC code	None;
Identifiers
	IUPAC name (2S)-N-{(1R)-1-[3,5-bis(trifluoromethyl); phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide;
CAS Number	334476-46-9 ; Mesylate: 334476-64-1 ;
PubChem CID	9832383;
IUPHAR/BPS	5757;
ChemSpider	8008111 ;
UNII	S052TOI9BI; Mesylate: OWR424W90Q ;
KEGG	D06293 ;
ChEMBL	ChEMBL522987 ;
CompTox Dashboard (EPA)	DTXSID50187092 ;
Chemical and physical data
Formula	C23H21F10N3O
Molar mass	545.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1cc(F)ccc1C2CNCCN2C(=O)N(C)C(C)c3cc(C(F)(F)F)cc(c3)C(F)(F)F;
	InChI InChI=1S/C23H24F7N3O/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3/t14-,20-/m1/s1 ; Key:SBBYBXSFWOLDDG-JLTOFOAXSA-N ;
	(what is this?) (verify)

Vestipitant (INN)^[1]^: 98 is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK₁ receptor. It is under development as a potential antiemetic and anxiolytic drug,^[2]^[3] and as a treatment for tinnitus^[4] and insomnia.^[5]